Disaggregated Revenues

9 Months Ended

Sep. 30, 2025

Disaggregation of Revenue [Abstract]

Disaggregated Revenues

Disaggregated Revenues

The following table provides information regarding total revenues (dollars in thousands):

	Three Months Ended September 30,				Nine Months Ended September 30,
	2025		2024		2025		2024
	(unaudited)				(unaudited)
Net product sales
Qelbree	$	81,416	$	62,359	$	223,708	$	166,857
GOCOVRI	40,849		35,657		108,198		93,922
APOKYN	10,387		19,867		38,183		53,811
Trokendi XR	10,043		15,318		34,037		48,393
Oxtellar XR	12,016		29,805		33,851		86,265
ONAPGO	6,806		—		8,410		—
Other(1)	7,025		7,296		22,138		22,053
Total net product sales	168,542		170,302		468,525		471,301
Collaboration revenue (ZURZUVAE)(2)	20,164		—		20,164		—
Royalty, licensing and other revenues	3,397		5,387		18,691		16,357
Total revenues	$	192,103	$	175,689	$	507,380	$	487,658

___________________________________________

(1) Includes net product sales of MYOBLOC, XADAGO and Osmolex ER.

(2) Includes the Company's proportionate share of net sales of ZURZUVAE.

In the third quarter of 2025, the Company continued to have favorable actual returns experience for Qelbree. As such, the Company changed its estimated provision for product returns based on the most recent experience. Provision for product returns related to prior year sales for the nine months period ended September 30, 2025 is approximately 3% of net product sales and is primarily attributable to Qelbree. Provision for product returns related to prior year sales for the nine months period ended September 30, 2024 was approximately 2% of net product sales.

We do not currently own or operate manufacturing facilities for the commercial production of any of our commercial products. We currently depend on third-party clinical manufacturing organizations (CMOs), who offer a comprehensive range of contract manufacturing and packaging services, in various countries for the supply of active product ingredients (API), finished goods for our commercial products. For most of our commercial products, we rely on single source suppliers to produce and package final dosage forms for our products and raw materials, including API.

On November 4, 2025, the Company announced that due to stronger than expected demand for ONAPGO, supplier constraints are impacting the Company's ability to fully meet this demand. ONAPGO is manufactured in Europe, supplied to us by our ONAPGO licensing partner, and packaged in the U.S. by a third-party CMO. We rely on single source suppliers to produce and package final dosage forms for ONAPGO. A change in supplier would require regulatory approval which could cause a delay in manufacturing and a possible loss of sales, which could affect future operating results adversely.